COMPANY
Synedgen, Inc.
Timeline
- Grant Government contract: $119M (up to, as announced), announced Oct 16, 2024. Source: company's own press page. source ↗
- Trial start Not phased (device or behavioral study): Efficacy of SynEx Wound Rinse in Civilian Surrogates of Combat Injury Wounds source ↗
- Trial start Not phased (device or behavioral study): SWC for Treatment of Superficial Partial-Thickness Burns source ↗
Funding
- Government contract: $119M (up to, as announced), announced Oct 16, 2024. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05877638 | SWC for Treatment of Superficial Partial-Thickness Burns | Not phased (device or behavioral study) | Terminated | Mar 27, 2023 | Jun 20, 2024 (actual) |
| NCT05743283 | Efficacy of SynEx Wound Rinse in Civilian Surrogates of Combat Injury Wounds | Not phased (device or behavioral study) | Recruiting | Apr 12, 2023 | 2025-09 (estimated) |
NIH awards 13
- NIH award 3U01EY030406-03S1 FY2022: $33,733 awarded for that fiscal year; activity U01 (OTHER_NIH); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Identification of lead compounds to topically source ↗
- NIH award 5U01EY030406-03 FY2021: $319,250 awarded for that fiscal year; activity U01 (OTHER_NIH); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Identification of lead compounds to topically source ↗
- NIH award 3U01EY030406-02S1 FY2020: $74,526 awarded for that fiscal year; activity U01 (OTHER_NIH); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Identification of lead compounds to topically source ↗
- NIH award 5U01EY030406-02 FY2020: $321,965 awarded for that fiscal year; activity U01 (OTHER_NIH); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Identification of lead compounds to topically source ↗
- NIH award 1U01EY030406-01 FY2019: $329,155 awarded for that fiscal year; activity U01 (OTHER_NIH); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Identification of lead compounds to topically source ↗
- NIH award 1R43DK098847-01A1 FY2016: $224,412 awarded for that fiscal year; activity R43 (SBIR); PI TOWNSEND, STACY MARIE; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Novel treatment for Crohn's disease and r source ↗
- NIH award 1R43DK107004-01 FY2015: $146,412 awarded for that fiscal year; activity R43 (SBIR); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Prevention and treatment of GI obstruction syndrome source ↗
- NIH contract (government contract; not a grant and not an investment round) 261201400011C-0-0-1 FY2014: $196,707 awarded for that fiscal year; activity N43 (OTHER_NIH); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Novel Topical Radiop source ↗
- NIH award 1R43HL118867-01 FY2013: $149,901 awarded for that fiscal year; activity R43 (SBIR); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Mucolytic for enhanced mucus and biofilm clearance source ↗
- NIH award 5R44DE019740-03 FY2012: $970,980 awarded for that fiscal year; activity R44 (SBIR); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Antimicrobial and Regenerative Treatment for Oral M source ↗
- NIH award 2R44DE019740-02 FY2011: $992,846 awarded for that fiscal year; activity R44 (SBIR); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Antimicrobial and Regenerative Treatment for Oral M source ↗
- NIH award 1R43AI085684-01A1 FY2010: $99,638 awarded for that fiscal year; activity R43 (SBIR); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Wound Decontamination for the Prevention and Treat source ↗
- NIH award 1R43DE019740-01 FY2009: $99,665 awarded for that fiscal year; activity R43 (SBIR); PI BAKER, SHENDA; recipient as written: SYNEDGEN, INC., CLAREMONT, CA. Prevention and Treatment of Oral Biofilms and Relate source ↗